Intravenous injection of mesenchymal stem cells ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01377870 (ClinicalTrials.gov) | December 2011 | 19/6/2011 | Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis | Effect and Side Effect of Mesenchymal Stem Cell in Multiple Sclerosis | Multiple Sclerosis | Biological: intravenous injection of mesenchymal stem cells;Biological: injection of cell free media | Royan Institute | NULL | Completed | 18 Years | 55 Years | All | 22 | Phase 1/Phase 2 | Iran, Islamic Republic of |